2026 Q1 -tulosraportti
Vain PDF
44 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 913 | - | - | ||
| 502 | - | - | ||
| 5 000 | - | - | ||
| 2 465 | - | - | ||
| 2 535 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·22 t sittenGood news is always welcome, thank you. Now there can hardly be any doubt that Weeco astrum10-10 will be a cash caw for Stenocare. Since Weeco atrum10-10 is considered and approved as general medicine, it will also not be affected if the subsidy for all medical cannabis is reduced. The subsidy for flower medicine and vaporizers stops as of January 1, 2027. In this regard, Hanf magasinet has written an article stating that the best alternative is oils and extracts. The German Ministry of Health has published Location: Page 2, section 2. The government's argument for excluding flowers: The text states that the German Ministry of Health (BMG) will limit health insurance coverage so that it will only apply to "extracts of standardized quality, finished medicinal products, and medicinal products with the active substances Dronabinol and Nabilon". Dried flowers are to be completely excluded. Why oil/extract is the safe alternative: Immediately after, the text describes the ministry's official justification to the market. The ministry argues that smoking/inhalation of flowers poses an unnecessary "erhøjet suchtgefahr" (increased risk of addiction) due to the excessively rapid absorption into the blood. Furthermore, they criticize that flowers as a natural product have too large fluctuations in active substance content. Conclusion in the legal text: The ministry states that "within the framework of a medical therapy, standardized extracts and finished medicinal products are principally indicated [red: the right choice] over getrockneten Blüten, as a higher standardization of active substance content can be achieved with these." I found the above with the help of Google, and it has been translated with the help of Google. Hanf magasin. https://www.hanf-magazin.com/en/gkv-soll-cannabis-blueten-nicht-mehr-erstatten/ German Ministry of Health https://cannabiswirtschaft.de/wp-content/uploads/2026/04/BvCW-Stellungnahme-BStabG-2026-04-19.pdf
·1 päivä sittenWho believes in this stock?
·1 päivä sittenWho is it that has gone on sale·1 päivä sittenYes, there can be many reasons for selling A sale is a sale I think there are very many who trade short-term and that is seen in the prices going up and down all the time For many of the sales that happen here make no sense to me Ex. Who buys and sells 500 pcs? There can't be profit in that, or for that matter 0-8000 pcs That makes no sense to me- ·2 päivää sittenHave bought more today 😊·1 päivä sittenI expect an upward revision of the financial statements. When StenoCare has settled with Weeco Pharma, which I expect to happen by mid-July at the latest, StenoCare must issue a press release about this as soon as possible. They must not wait until they publish the financial statements on August 5. It's simple math, and I've taken all the numbers from the low end. Based on that, you can estimate what you think is most likely. Management has a guidance that StenoCare will earn 12-15 million kroner in 2026. In Q1 they earned 3 million kr. based on guidance, and to have something to calculate with, I expect management believes there will be flat earnings from Denmark. 12 million. The remaining 3 million must come from Germany. We don't know the license agreement in detail, so I'm guessing they get 100 kr. per bottle. A user typically buys 4-6 bottles per year, so I've calculated with 4 per year. In Germany, there are on average 250 weekdays in 2026. We must include that ADREX in 2025. has promoted Astrum10--10 to doctors. So these people who have received a prescription for the oil will also buy in 2026. Based on these figures, I can see that management has expected that a maximum of 30 bottles per day will be sold in Germany. Since May 13, we have been able to see that things are progressing, and we know that there is an unreported number that is also unknown. I'm guessing that doctors are in the process of finding alternatives to Blomster og damper, because the subsidy will be abolished on January 1, 2027. Here, some of these people will get a prescription for Weeco Astrum10-10. The number is unknown. Weeco Astrum10-10 will be sent out to at least 500 pharmacies (Canngo) This means that 0.06 bottles will be sold over the counter per pharmacy per day, if ST and Pj guidance holds. I think there will be an update in Q2, what do you think?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
44 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·22 t sittenGood news is always welcome, thank you. Now there can hardly be any doubt that Weeco astrum10-10 will be a cash caw for Stenocare. Since Weeco atrum10-10 is considered and approved as general medicine, it will also not be affected if the subsidy for all medical cannabis is reduced. The subsidy for flower medicine and vaporizers stops as of January 1, 2027. In this regard, Hanf magasinet has written an article stating that the best alternative is oils and extracts. The German Ministry of Health has published Location: Page 2, section 2. The government's argument for excluding flowers: The text states that the German Ministry of Health (BMG) will limit health insurance coverage so that it will only apply to "extracts of standardized quality, finished medicinal products, and medicinal products with the active substances Dronabinol and Nabilon". Dried flowers are to be completely excluded. Why oil/extract is the safe alternative: Immediately after, the text describes the ministry's official justification to the market. The ministry argues that smoking/inhalation of flowers poses an unnecessary "erhøjet suchtgefahr" (increased risk of addiction) due to the excessively rapid absorption into the blood. Furthermore, they criticize that flowers as a natural product have too large fluctuations in active substance content. Conclusion in the legal text: The ministry states that "within the framework of a medical therapy, standardized extracts and finished medicinal products are principally indicated [red: the right choice] over getrockneten Blüten, as a higher standardization of active substance content can be achieved with these." I found the above with the help of Google, and it has been translated with the help of Google. Hanf magasin. https://www.hanf-magazin.com/en/gkv-soll-cannabis-blueten-nicht-mehr-erstatten/ German Ministry of Health https://cannabiswirtschaft.de/wp-content/uploads/2026/04/BvCW-Stellungnahme-BStabG-2026-04-19.pdf
- ·1 päivä sittenWho believes in this stock?
- ·1 päivä sittenWho is it that has gone on sale·1 päivä sittenYes, there can be many reasons for selling A sale is a sale I think there are very many who trade short-term and that is seen in the prices going up and down all the time For many of the sales that happen here make no sense to me Ex. Who buys and sells 500 pcs? There can't be profit in that, or for that matter 0-8000 pcs That makes no sense to me
- ·2 päivää sittenHave bought more today 😊·1 päivä sittenI expect an upward revision of the financial statements. When StenoCare has settled with Weeco Pharma, which I expect to happen by mid-July at the latest, StenoCare must issue a press release about this as soon as possible. They must not wait until they publish the financial statements on August 5. It's simple math, and I've taken all the numbers from the low end. Based on that, you can estimate what you think is most likely. Management has a guidance that StenoCare will earn 12-15 million kroner in 2026. In Q1 they earned 3 million kr. based on guidance, and to have something to calculate with, I expect management believes there will be flat earnings from Denmark. 12 million. The remaining 3 million must come from Germany. We don't know the license agreement in detail, so I'm guessing they get 100 kr. per bottle. A user typically buys 4-6 bottles per year, so I've calculated with 4 per year. In Germany, there are on average 250 weekdays in 2026. We must include that ADREX in 2025. has promoted Astrum10--10 to doctors. So these people who have received a prescription for the oil will also buy in 2026. Based on these figures, I can see that management has expected that a maximum of 30 bottles per day will be sold in Germany. Since May 13, we have been able to see that things are progressing, and we know that there is an unreported number that is also unknown. I'm guessing that doctors are in the process of finding alternatives to Blomster og damper, because the subsidy will be abolished on January 1, 2027. Here, some of these people will get a prescription for Weeco Astrum10-10. The number is unknown. Weeco Astrum10-10 will be sent out to at least 500 pharmacies (Canngo) This means that 0.06 bottles will be sold over the counter per pharmacy per day, if ST and Pj guidance holds. I think there will be an update in Q2, what do you think?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 913 | - | - | ||
| 502 | - | - | ||
| 5 000 | - | - | ||
| 2 465 | - | - | ||
| 2 535 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
44 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·22 t sittenGood news is always welcome, thank you. Now there can hardly be any doubt that Weeco astrum10-10 will be a cash caw for Stenocare. Since Weeco atrum10-10 is considered and approved as general medicine, it will also not be affected if the subsidy for all medical cannabis is reduced. The subsidy for flower medicine and vaporizers stops as of January 1, 2027. In this regard, Hanf magasinet has written an article stating that the best alternative is oils and extracts. The German Ministry of Health has published Location: Page 2, section 2. The government's argument for excluding flowers: The text states that the German Ministry of Health (BMG) will limit health insurance coverage so that it will only apply to "extracts of standardized quality, finished medicinal products, and medicinal products with the active substances Dronabinol and Nabilon". Dried flowers are to be completely excluded. Why oil/extract is the safe alternative: Immediately after, the text describes the ministry's official justification to the market. The ministry argues that smoking/inhalation of flowers poses an unnecessary "erhøjet suchtgefahr" (increased risk of addiction) due to the excessively rapid absorption into the blood. Furthermore, they criticize that flowers as a natural product have too large fluctuations in active substance content. Conclusion in the legal text: The ministry states that "within the framework of a medical therapy, standardized extracts and finished medicinal products are principally indicated [red: the right choice] over getrockneten Blüten, as a higher standardization of active substance content can be achieved with these." I found the above with the help of Google, and it has been translated with the help of Google. Hanf magasin. https://www.hanf-magazin.com/en/gkv-soll-cannabis-blueten-nicht-mehr-erstatten/ German Ministry of Health https://cannabiswirtschaft.de/wp-content/uploads/2026/04/BvCW-Stellungnahme-BStabG-2026-04-19.pdf
- ·1 päivä sittenWho believes in this stock?
- ·1 päivä sittenWho is it that has gone on sale·1 päivä sittenYes, there can be many reasons for selling A sale is a sale I think there are very many who trade short-term and that is seen in the prices going up and down all the time For many of the sales that happen here make no sense to me Ex. Who buys and sells 500 pcs? There can't be profit in that, or for that matter 0-8000 pcs That makes no sense to me
- ·2 päivää sittenHave bought more today 😊·1 päivä sittenI expect an upward revision of the financial statements. When StenoCare has settled with Weeco Pharma, which I expect to happen by mid-July at the latest, StenoCare must issue a press release about this as soon as possible. They must not wait until they publish the financial statements on August 5. It's simple math, and I've taken all the numbers from the low end. Based on that, you can estimate what you think is most likely. Management has a guidance that StenoCare will earn 12-15 million kroner in 2026. In Q1 they earned 3 million kr. based on guidance, and to have something to calculate with, I expect management believes there will be flat earnings from Denmark. 12 million. The remaining 3 million must come from Germany. We don't know the license agreement in detail, so I'm guessing they get 100 kr. per bottle. A user typically buys 4-6 bottles per year, so I've calculated with 4 per year. In Germany, there are on average 250 weekdays in 2026. We must include that ADREX in 2025. has promoted Astrum10--10 to doctors. So these people who have received a prescription for the oil will also buy in 2026. Based on these figures, I can see that management has expected that a maximum of 30 bottles per day will be sold in Germany. Since May 13, we have been able to see that things are progressing, and we know that there is an unreported number that is also unknown. I'm guessing that doctors are in the process of finding alternatives to Blomster og damper, because the subsidy will be abolished on January 1, 2027. Here, some of these people will get a prescription for Weeco Astrum10-10. The number is unknown. Weeco Astrum10-10 will be sent out to at least 500 pharmacies (Canngo) This means that 0.06 bottles will be sold over the counter per pharmacy per day, if ST and Pj guidance holds. I think there will be an update in Q2, what do you think?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 913 | - | - | ||
| 502 | - | - | ||
| 5 000 | - | - | ||
| 2 465 | - | - | ||
| 2 535 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt